GSK thinks small as part of new R&D approach

07/1/2010 | Wall Street Journal, The

GlaxoSmithKline is breaking up its research-and-development team into smaller, more specialized groups in an effort to bypass the bureaucracy that has hampered it from producing many new drugs over the past decade. GSK hopes these groups will imitate the success of smaller biotech companies. However, some analysts have questioned the approach. "The problem with big companies trying to act like biotechs is that people who like the really entrepreneurial culture of a biotech go to biotechs," one health care analyst said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC